Advertisement
YOU ARE HERE: LAT HomeCollectionsStaar Surgical Co
IN THE NEWS

Staar Surgical Co

FEATURED ARTICLES
BUSINESS
February 3, 2005 | From Reuters
Staar Surgical Co., a maker of lenses and devices used in ophthalmology, said the Food and Drug Administration might take further action against it. The FDA last year warned Staar it might suspend operations at its Monrovia plant because of flaws in the company's surgically implanted contact lens. Staar shares fell 25 cents to $6.15 on Nasdaq.
ARTICLES BY DATE
BUSINESS
June 28, 2007 | From Times Wire Services
Staar Surgical Co., a Monrovia-based maker of implantable contact lenses, said it had received a letter from the Food and Drug Administration warning the company that its clinical study procedures did not comply with federal rules.
Advertisement
BUSINESS
March 11, 2005 | Debora Vrana, Times Staff Writer
Shares of Staar Surgical Co. plummeted 22% on Thursday after the Monrovia maker of an implantable contact lens said its outside accountants were doubtful about the company's ability to stay in business. Staar reported a larger-than-expected loss for the fourth quarter late Wednesday and warned that planned cost-cutting moves wouldn't be enough to return the company to profitability.
BUSINESS
December 18, 1989 | From United Press International
Staar Directors Sued Over Loan: A San Dimas company filed suit in Los Angeles County Superior Court Wednesday to collect a $325,000 loan made to directors of Staar Surgical Co. while they battled the chairman for control of the small Monrovia company. Vision Technologies International Inc. lent the money to officers and directors of Staar in September and October of 1989 on the condition that it be repaid with interest once the five-member board had been legally reinstated, the suit said.
BUSINESS
March 12, 1985
Michael J. Ram has joined Staar Surgical Co., Monrovia, as vice president-research and development.
BUSINESS
June 28, 2007 | From Times Wire Services
Staar Surgical Co., a Monrovia-based maker of implantable contact lenses, said it had received a letter from the Food and Drug Administration warning the company that its clinical study procedures did not comply with federal rules.
BUSINESS
March 15, 1990 | Leslie Berkman and Gregory Crouch, Times staff writers
Rights Acquired: Chiron Ophthalmics Inc. in Irvine has agreed to buy the marketing, manufacturing and licensing rights to a line of silicone intra-ocular lenses made by Staar Surgical Co. in Monrovia. Staar will receive up to $4 million in prepaid royalties. The agreement between Staar and Chiron, supplier of lenses and other products to ophthalmic surgeons, has generated some controversy recently. Former Staar president Thomas R.
BUSINESS
February 21, 1997 | Times Staff and Wire Reports
Staar Surgical Co. said it received U.S. government approval to begin trials on people of its implantable contact lenses, the only device of its kind. The Food and Drug Administration ruled that the company can implant 10 of the lenses in patients at four eye clinics, the Monrovia-based medical products maker said. Staar Surgical's lenses are implanted in the eye behind the iris and in front of the natural lens, the company said. Staar Surgical shares rose 50 cents to close at $13.375 on
BUSINESS
January 7, 2004 | From Bloomberg News
Staar Surgical Co., a Monrovia maker of implanted contact lenses, was cited by the Food and Drug Administration for failure to ensure that complaints about the devices were properly investigated. The shares fell 18%. The company didn't adequately investigate complaints that it received about blurred and cloudy vision linked to its products, the agency said in a letter to the company dated Dec. 22 and posted on the FDA's website.
BUSINESS
February 3, 2005 | From Reuters
Staar Surgical Co., a maker of lenses and devices used in ophthalmology, said the Food and Drug Administration might take further action against it. The FDA last year warned Staar it might suspend operations at its Monrovia plant because of flaws in the company's surgically implanted contact lens. Staar shares fell 25 cents to $6.15 on Nasdaq.
BUSINESS
January 7, 2004 | From Bloomberg News
Staar Surgical Co., a Monrovia maker of implanted contact lenses, was cited by the Food and Drug Administration for failure to ensure that complaints about the devices were properly investigated. The shares fell 18%. The company didn't adequately investigate complaints that it received about blurred and cloudy vision linked to its products, the agency said in a letter to the company dated Dec. 22 and posted on the FDA's website.
BUSINESS
October 7, 2003 | From Bloomberg News
Shares of Staar Surgical Co. fell 13% on Monday after a Food and Drug Administration panel expressed concern about the company's experimental implanted lens for treating nearsightedness. On Friday, an FDA advisory panel recommended that the agency approve the device with several conditions, including longer-term patient follow-up exams. Members of the panel said they were troubled by cell loss in the cornea after surgery. The FDA usually follows its panel's advice.
BUSINESS
August 2, 2001 | From Bloomberg News
Staar Surgical Co., a Monrovia-based medical-device maker whose shares have fallen 68% this year, said Wednesday that it's cutting 75 jobs, or a quarter of its work force worldwide, to boost profit. The maker of intra-ocular lenses and contact lenses will take $12 million in charges over the next several quarters as part of the cost-cutting moves. Staar said it will shut some overseas operations. The firm isn't yet disclosing where the closures will be, Chief Financial Officer John Santos said.
BUSINESS
June 13, 2001 | Reuters
Staar Surgical Co., a maker of optical medical devices, said it has recalled a type of lens used in cataract procedures due to a potential packaging flaw that could breach the sterility of the lens. The Monrovia-based company said it is too soon to assess costs associated with the recall of the Model CQ-2005V, a three-piece Collamer intraocular lens. The company said the pouches in which the lenses are packaged could possibly open while in transit, possibly causing a breach in their sterility.
BUSINESS
December 21, 2000
* STAAR Surgical Co., a Monrovia-based maker of ophthalmic medical devices, has appointed David Bailey president and chief executive. He also will be a member of the company's board of directors. Bailey is a former global president of CIBA Vision Corp.'s surgical business unit in Atlanta. * Avery Dennison Corp., the Pasadena-based label maker, has announced promotions of three members of its senior management team.
BUSINESS
August 2, 2001 | From Bloomberg News
Staar Surgical Co., a Monrovia-based medical-device maker whose shares have fallen 68% this year, said Wednesday that it's cutting 75 jobs, or a quarter of its work force worldwide, to boost profit. The maker of intra-ocular lenses and contact lenses will take $12 million in charges over the next several quarters as part of the cost-cutting moves. Staar said it will shut some overseas operations. The firm isn't yet disclosing where the closures will be, Chief Financial Officer John Santos said.
BUSINESS
November 9, 2000 | Bloomberg News
Monrovia-based Staar Surgical Co. won the backing of an expert U.S. government panel for a wick-like device that's implanted in the eye to treat glaucoma. The Food and Drug Administration advisory panel voted to recommend the agency approve the device for use once glaucoma drugs stopped working. Panelists noted that the device wasn't directly judged against the surgical treatment now used, making comparisons to that standard treatment difficult.
BUSINESS
August 7, 1997 | (Bloomberg News)
Staar Surgical Co. said it received Food and Drug Administration approval to begin the second phase of clinical trials of its implantable contact lenses to correct nearsightedness. The FDA will allow the Monrovia-based company to implant 62 of the lenses in patients. In the first phase of the trials, seven of the 10 patients tested improved their vision to 20/20, or perfect, from being legally blind without glasses. Shares of Staar Surgical rose $1.13 to close at $14.50 in Nasdaq trading.
Los Angeles Times Articles
|